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microRNA profiling in lung tissue 
and bronchoalveolar lavage of 
cigarette smoke-exposed mice and 
in COPD patients: a translational 
approach
Griet Conickx 1, Francisco Avila Cobos  2, Maarten van den Berge3, Alen Faiz3, Wim Timens 
 4, Pieter S. Hiemstra  5, Guy F. Joos 1, Guy G. Brusselle 1, Pieter Mestdagh 2 & Ken R. 
Bracke 1
Chronic obstructive pulmonary disease (COPD) is characterized by a progressive airflow limitation 
and is associated with a chronic inflammatory response in both airways and lungs. microRNAs 
(miRNAs) are often highly conserved between species and have an intricate role within homeostatic 
conditions and immune responses. Also, miRNAs are dysregulated in smoking-associated diseases. 
We investigated the miRNA profile of 523 miRNAs by stem-loop RT-qPCR in lung tissue and cell-free 
bronchoalveolar lavage (BAL) supernatant of mice exposed to air or cigarette smoke (CS) for 4 or 24 
weeks. After 24 weeks of CS exposure, 31 miRNAs were differentially expressed in lung tissue and 78 
in BAL supernatant. Next, we correlated the miRNA profiling data to inflammation in BAL and lung, 
obtained by flow cytometry or ELISA. In addition, we surveyed for overlap with newly assessed miRNA 
profiles in bronchial biopsies and with previously assessed miRNA profiles in lung tissue and induced 
sputum supernatant of smokers with COPD. Several miRNAs showed concordant differential expression 
between both species including miR-31*, miR-155, miR-218 and let-7c. Thus, investigating miRNA 
profiling data in different compartments and both species provided accumulating insights in miRNAs 
that may be relevant in CS-induced inflammation and the pathogenesis of COPD.
Chronic Obstructive Pulmonary Disease (COPD) is a debilitating respiratory condition characterized by a 
progressive and irreversible airflow limitation due to an abnormal inflammatory response to inhaled noxious 
particles or gases1–3. The pathology comprises a mixture of small airway obstruction and destruction of lung 
parenchyma (emphysema); their relative contribution varying between patients and within the lung4. The main 
risk factor for COPD is cigarette smoking. However, only 20% of smokers develop COPD, suggesting that genetic 
susceptibility or alterations in the epigenetic machinery may be of importance in the development of the disease.
microRNAs (miRNAs), i.e. small non-coding RNAs, are key regulators in diverse biological pathways. One 
single miRNA can bind to target sequences in multiple mRNAs, typically resulting in mRNA degradation or 
translational inhibition5. By doing so, miRNAs embed a post-transcriptional control within multiple gene signa-
ling cascades. Also, certain miRNAs are critically involved in immune cell development and function. Given this 
far-reaching influence, it is not surprising that altered miRNA levels contribute to disease pathogenesis6.
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Ideally, differentially expressed miRNAs in disease versus control can serve as biomarkers of disease initi-
ation/progression or as therapeutic target. In lungs of patients with COPD, we have shown the involvement of 
down-regulated miRNA-218-5p in recruiting inflammatory cells towards the airways, thereby assisting in the 
sustained inflammation7. In sputum of patients with COPD, down-regulation of let-7c was inversely correlated 
with soluble TNFR-II, a receptor implicated in COPD pathogenesis8.
The expression of miRNAs is described to be altered after cigarette smoke (CS) exposure in lungs of mice and 
patients with COPD9–12. Smoking can potentiate inflammatory processes by affecting the expression of miRNAs 
that play a key role in immune responses. To obtain full insights in the CS-induced alterations in murine miRNA 
levels and immune cell populations in the lung, we performed an RT-qPCR-based miRNA profiling in bronchoal-
veolar lavage (BAL) supernatant and lung tissue of mice that were exposed to air or CS for 4 or 24 weeks, comple-
mented with data on inflammation in BAL and lungs. Moreover, using a translational approach, we checked for 
overlapping miRNAs in lung tissue between CS-exposed mice and bronchial biopsies of patients with COPD. We 
also assessed overlap in differentially expressed miRNAs with previously reported studies in patients with COPD. 
Overall, this information will highlight relevant miRNAs in the CS-induced inflammation.
Results
miRNA expression profiling in lung tissue of air- and CS-exposed mice. miRNA profiling was per-
formed on lung tissue of C57BL/6 mice (8 per group), that were exposed to either air or CS for 4 or 24 weeks. Of 
the 523 miRNAs tested by stem-loop RT-qPCR, 255 miRNAs could be detected. After 4 weeks of CS exposure, 
9 miRNAs exhibited differential pulmonary expression compared to the air-exposed mice (4 down-regulated 
and 5 up-regulated). After 24 weeks of CS exposure, 31 miRNAs showed a significant differential expression of 
which 16 were down-regulated and 15 were up-regulated. The results are represented in Fig. 1. A list of all differ-
entially expressed miRNAs in lung tissue can be found in Tables 1 and 2 and are annotated on the volcano plots 
in Figure S1.
In lung tissue, all 5 significantly up-regulated miRNAs after 4 weeks of CS exposure, were even more 
increased following chronic CS exposure, indicating a robust and progressive miRNA signature. On top of the 
list, miR-135b displayed the highest fold change in lung tissue (Fold change = 13.59, Table 2). From the signifi-
cantly down-regulated miRNAs following 4 weeks of CS exposure in lung, only miR-322* was still significantly 
decreased after 24 weeks of CS exposure (Fig. 1e).
miRNA expression profiling in BAL supernatant of air- and CS-exposed mice. miRNA expression 
profiling was performed on cell-free BAL supernatant of mice exposed to air or CS for 4 or 24 weeks. Of the 523 
miRNAs evaluated, 160 miRNAs could be detected in BAL supernatant. After 4 weeks of CS exposure, only 6 
miRNAs were significantly differentially expressed (4 down-regulated and 2 up-regulated). However, after 24 
weeks of CS smoke exposure, 78 miRNAs exhibited significant differential expression in BAL supernatant of 
which 40 were down-regulated and 38 were up-regulated. The results are represented in Fig. 2. A list of all dif-
ferentially expressed miRNAs in BAL supernatant can be found in Tables 3–5 and are annotated on the volcano 
plots in Figure S2.
In BAL supernatant, let-7b and let-7c were significantly reduced after 4 and 24 weeks of CS exposure (Fig. 2e). 
Moreover, miR-680 showed the highest fold change (Fold change = 20.92, Table 4) following long-term smoking.
Differentially expressed miRNAs following CS exposure in both lung tissue and BAL superna-
tant. Following subacute CS exposure, only miR-138 overlaps as being differentially expressed in both lung 
and BAL supernatant (Fig. 3a). Following chronic CS exposure, 12 miRNAs (miR-146a, miR-148a, miR-152, miR-
21, miR-26a, miR-30a-5p, miR-30c, miR-31, miR-31*, miR-342-3p, miR-376b* and miR-449) were differentially 
expressed in both lung tissue and BAL supernatant of which 10 showed concordant up- or down-regulation. Only 
miR-449 and miR-148a displayed different expression patterns in the two compartments (Fig. 3b).
Furthermore, a multidimensional scaling plot (Supplementary Figure S3) showed a clear separation between 
normalized miRNA profiles (only containing miRNAs expressed in both fractions) from BAL supernatant and 
Up-regulated in CS-exposed mice miRBase release 21 Fold change Adjusted p-value
mmu-miR-135b mmu-miR-135b-5p 4.110 0.015
mmu-miR-138 mmu-miR-138-5p 2.160 0.015
mmu-miR-21 mmu-miR-21a-5p 1.747 0.015
mmu-miR-155 mmu-miR-155-5p 1.580 0.021
mmu-miR-31 mmu-miR-31-5p 1.238 0.024
Down-regulated in CS-exposed mice miRBase release 21 Fold change Adjusted p-value
mmu-miR-322x mmu-miR-322-3p 1.695 0.015
mmu-miR-351 mmu-miR-351-5p 1.585 0.024
mmu-miR-434-3p mmu-miR-434-3p 1.531 0.024
mmu-miR-136 mmu-miR-136-5p 1.531 0.021
Table 1. Differentially expressed microRNAs in murine lung tissue following 4 weeks of cigarette smoke 
exposure. First column: annotation of miRNA during microRNA profiling; Second column: annotation of 
miRNA according to miRBase release 21.
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Figure 1. miRNA expression profiling in lung tissue of air- and CS-exposed mice. Volcano plots showing the 
differential miRNA expression (in fold change on the x-axis) and significance level (−log10-adjusted p-value 
on y-axis). The detected miRNAs are plotted as black dots. The horizontal line indicates the 0.05 significance 
level. In the heatmaps, only the significantly differentially expressed miRNAs are represented. These were 
hierarchically clustered across the air- and smoke-exposed groups. Each row represents a miRNA and each 
column represents a murine lung sample. The color code indicates the expression level: red = higher expression 
following CS exposure, blue = lower expression, grey = miRNA was not detected (“NA” values). (a) Heatmap 
showing the differentially expressed miRNAs in murine lung tissue following subacute (4 weeks) air or CS 
exposure. (b) Volcano plot representing the miRNA profiling data following subacute CS exposure compared to 
air exposure. (c) Heatmap showing the differentially expressed miRNAs in murine lung tissue following chronic 
(24 weeks) air or CS exposure. (d) Volcano plot representing the miRNA profiling data following chronic CS 
exposure versus air exposure. (e) Overlap in differentially expressed miRNAs in murine lung tissue between 
subacute and chronic CS exposure compared to air exposure. Volcano plots with annotated miRNAs can be 
found in the online supplement (Figure S1).
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lung tissue, indicating two compartments with different cellular identity, anatomical structure and organization. 
miRNA profiles of lung tissue clustered more together than miRNA profiles of BAL supernatant. Moreover, fol-
lowing 24 weeks of CS exposure in BAL, a larger separation in miRNA profiles was noticed compared to lung, 
underlining the more relative diversity in cell types in BAL following long-term CS exposure. Also, due to this fact 
and a more activated state of immune cells, a global increase in miRNA abundance was found in BAL supernatant 
following 24 weeks of CS exposure (Mann-Whitney U test; p-value = 0.007, Supplementary Figure S4).
Inflammation in lungs and BAL fluid of mice following CS exposure. Four weeks of CS exposure 
induced an inflammatory response in lung and BAL with recruitment of inflammatory cells and activation of 
immune signaling. In BAL fluid, there was a significant increase in total cell numbers (p-value = 0.007, Fig. 4a) 
with more diversity in immune cell subsets such as a significant increase in macrophages (p-value = 0.0104), neu-
trophils (p-value = 0.00016), dendritic cells (DCs) (p-value = 0.00016) and CD4+ (p-value = 0.007) and CD8+T 
lymphocytes (p-value = 0.0104) compared with air-exposed mice (Fig. 4b–f). After 24 weeks of CS exposure, the 
inflammatory response was severely augmented in BAL with a strong increase in total cell numbers as well as in 
macrophages, neutrophils, DCs and T lymphocytes (all p-values < 0.001, Fig. 4a–f).
In addition, in lung tissue, the increase in dendritic cells is corresponding to the smoke-induced inflammation 
and proportionally to subacute or chronic CS exposure compared with air exposure (Supplementary Figure S5a). 
Also, B cell numbers were augmented following chronic CS exposure (Supplementary Figure S5b).
Correlation of miRNA expression with inflammatory cell subsets in lung tissue and BAL super-
natant. To assess whether the change in cell types following CS exposure could be associated with the altera-
tion in miRNA expression, we correlated the miRNA expression with populations of immune cells and levels of 
inflammatory chemokines. After subacute CS exposure, miR-135b correlated strongly with percentage DCs (adj. 
p-value = 0.017, Fig. 5a). Following chronic CS exposure, miR-155 correlated significantly with percentage B cells 
Up-regulated in CS-exposed mice miRBase release 21 Fold change Adjusted p-value
mmu-miR-135b mmu-miR-135b-5p 13.593 0.004
mmu-miR-135a mmu-miR-135a-5p 8.557 0.014
mmu-miR-21 mmu-miR-21a-5p 3.103 0.004
mmu-miR-155 mmu-miR-155-5p 2.274 0.004
mmu-miR-146a mmu-miR-146a-5p 1.969 0.004
mmu-miR-138 mmu-miR-138-5p 1.908 0.007
mmu-miR-449b mmu-miR-449c-5p 1.764 0.015
mmu-miR-31x mmu-miR-31-3p 1.452 0.004
mmu-miR-18a mmu-miR-18a-5p 1.435 0.046
mmu-miR-31 mmu-miR-31-5p 1.403 0.040
mmu-miR-449 mmu-miR-449a-5p 1.386 0.046
mmu-miR-342-3p mmu-miR-342-3p 1.322 0.004
mmu-miR-200c mmu-miR-200c-3p 1.229 0.046
mmu-miR-148a mmu-miR-148a-3p 1.186 0.046
mmu-miR-191 mmu-miR-191-5p 1.148 0.040
Down-regulated in CS-exposed mice miRBase release 21 Fold change Adjusted p-value
mmu-miR-322x mmu-miR-322-3p 1.953 0.010
mmu-miR-489 mmu-miR-489-3p 1.890 0.033
mmu-miR-1 mmu-miR-1a-3p 1.733 0.023
mmu-miR-133b mmu-miR-133b-3p 1.553 0.033
mmu-miR-503 mmu-miR-503-5p 1.520 0.015
mmu-miR-376bx mmu-miR-376b-5p 1.493 0.046
mmu-miR-365 mmu-miR-365-3p 1.479 0.007
mmu-miR-149 mmu-miR-149-5p 1.443 0.010
mmu-miR-503x mmu-miR-503-3p 1.433 0.040
mmu-miR-224 mmu-miR-224-5p 1.393 0.046
mmu-miR-26a mmu-miR-26a-5p 1.362 0.010
mmu-miR-145 mmu-miR-145a-5p 1.359 0.004
mmu-miR-676 mmu-miR-676-3p 1.302 0.023
mmu-miR-152 mmu-miR-152-3p 1.242 0.040
mmu-miR-30c mmu-miR-30c-5p 1.241 0.046
mmu-miR-30a-5p mmu-miR-30a-5p 1.127 0.040
Table 2. Differentially expressed microRNAs in murine lung tissue following 24 weeks of cigarette smoke 
exposure. First column: annotation of miRNA during microRNA profiling; Second column: annotation of 
miRNA according to miRBase release 21.
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Figure 2. miRNA expression profiling in cell-free BAL supernatant of air- and CS-exposed mice. Volcano 
plots showing the differential miRNA expression (in fold change on the x-axis) and significance level (-log10-
adjusted p-value on y-axis). The detected miRNAs are plotted as black dots. The horizontal line indicates the 0.05 
significance level. In the heatmaps, only the significantly differentially expressed miRNAs are represented. These 
were hierarchically clustered across the air- and smoke-exposed groups. Each row represents a miRNA and each 
column represents a murine BAL supernatant sample. The color code indicates the expression level: red = higher 
expression following CS exposure, blue = lower expression, grey = miRNA was not detected (“NA” values). (a) 
Heatmap showing the differentially expressed miRNAs in murine BAL supernatant following subacute (4 weeks) 
air or CS exposure. (b) Volcano plot representing the miRNA profiling data in BAL supernatant following subacute 
CS exposure compared to air exposure. (c) Heatmap showing the differentially expressed miRNAs in murine BAL 
supernatant following chronic (24 weeks) air or CS exposure. (d) Volcano plot representing the miRNA profiling 
data in BAL supernatant following chronic CS exposure versus air exposure. (e) Overlap in differentially expressed 
miRNAs in murine BAL supernatant between subacute and chronic CS exposure compared to air exposure. 
Volcano plots with annotated miRNAs can be found in the online supplement (Figure S2).
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Up-regulated in CS-exposed mice miRBase release 21 Fold change Adjusted p-value
mmu-miR-138 mmu-miR-138-5p 2.048 0.044
mmu-miR-182 mmu-miR-182-5p 1.727 0.050
Down-regulated in CS-exposed mice miRBase release 21 Fold change Adjusted p-value
mmu-miR-676 mmu-miR-676-3p 1.678 0.044
mmu-miR-574-3p mmu-miR-574-3p 1.458 0.044
mmu-let-7c mmu-let-7c-5p 1.433 0.050
mmu-let-7b mmu-let-7b-5p 1.325 0.025
Table 3. Differentially expressed microRNAs in bronchoalveolar lavage supernatant following 4 weeks of 
cigarette smoke exposure. First column: annotation of miRNA during microRNA profiling; Second column: 
annotation of miRNA according to miRBase release 21.
Up-regulated in CS-exposed mice miRBase release 21 Fold change Adjusted p-value
mmu-miR-680 mmu-miR-680 20.924 0.005
mmu-miR-221 mmu-miR-221-3p 14.606 0.003
mmu-miR-297ax mmu-miR-297a-3p 6.614 0.007
mmu-miR-150 mmu-miR-150-5p 6.382 0.002
mmu-miR-142-5p mmu-miR-142a-5p 4.554 0.003
mmu-miR-685 4.256 0.002
mmu-miR-139-5p mmu-miR-139-5p 3.853 0.002
mmu-miR-146a mmu-miR-146a-5p 3.573 0.002
mmu-miR-706 mmu-miR-706 3.531 0.002
mmu-miR-142-3p mmu-miR-142a-3p 3.382 0.002
mmu-miR-340 mmu-miR-340-3p 2.900 0.010
mmu-miR-592 mmu-miR-592-5p 2.684 0.014
mmu-let-7ax mmu-let-7a-1-3p 2.294 0.007
mmu-let-7i mmu-let-7i-5p 2.165 0.007
mmu-miR-218-1x mmu-miR-218-1-3p 2.149 0.049
mmu-miR-690 mmu-miR-690 2.143 0.007
mmu-miR-140-3p mmu-miR-140-3p 2.043 0.002
mmu-miR-9x mmu-miR-9-3p 2.042 0.014
mmu-miR-25 mmu-miR-25-3p 2.030 0.004
mmu-miR-20b mmu-miR-20b-5p 1.964 0.007
mmu-miR-342-3p mmu-miR-342-3p 1.954 0.018
mmu-miR-31x mmu-miR-31-3p 1.923 0.010
mmu-miR-21 mmu-miR-21a-5p 1.909 0.002
mmu-miR-130b mmu-miR-130b-3p 1.807 0.004
mmu-miR-652 mmu-miR-652-3p 1.717 0.018
mmu-miR-15b mmu-miR-15b-5p 1.625 0.041
mmu-miR-146b mmu-miR-146b-5p 1.619 0.007
mmu-miR-19a mmu-miR-19a-3p 1.580 0.006
mmu-miR-484 mmu-miR-484 1.550 0.004
mmu-miR-93 mmu-miR-93-5p 1.501 0.005
mmu-miR-672 mmu-miR-672-5p 1.471 0.007
mmu-miR-15a mmu-miR-15a-5p 1.403 0.036
mmu-miR-31 mmu-miR-31-5p 1.397 0.018
mmu-miR-27a mmu-miR-27a-3p 1.392 0.007
mmu-miR-20a mmu-miR-20a-5p 1.373 0.002
mmu-miR-92 mmu-miR-92a-3p 1.365 0.007
mmu-miR-186 mmu-miR-186-5p 1.289 0.002
mmu-miR-140 mmu-miR-140-5p 1.261 0.018
Table 4. Up-regulated microRNAs in bronchoalveolar lavage supernatant following 24 weeks of cigarette 
smoke exposure. First column: annotation of miRNA during microRNA profiling; Second column: annotation 
of miRNA according to miRBase release 21.
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(adj. p-value = 0.0067, Fig. 5b) and miR-152, miR-30a-5p, miR-30c, miR-218 and miR-26a correlated with several 
immune cell types in lung tissue.
In BAL supernatant, miR-21 correlated significantly with macrophage numbers and MCP-1 (adj. 
p-value = 0.0014, Fig. 5c), while miR-142-3p, miR-21, miR-146a as well as miR-218 and let-7 family members 
correlated with neutrophil numbers (Fig. 5d,e). miR-26a and miR-146a correlated with several immune cell types 
whereas miR-31* correlated significantly with DC numbers (adj. p-value = 0.026).
Overlap in miRNA expression pattern between chronic CS-exposed mice and patients with 
COPD. Generally, miRNAs are highly conserved RNA molecules. Therefore, we evaluated a possible overlap 
in miRNA expression between mice following long-term CS exposure and patients with COPD.
First, we evaluated the overlap in lung tissue of mice exposed to CS for 24 weeks and our previously reported 
miRNA profiling in lung tissue of current smoking COPD patients compared to never-smokers without COPD, 
all assessed by stem-loop RT-qPCR7. Interestingly, miR-135b and miR-155 were significantly up-regulated, both 
in COPD patients (Adj. p-value (miR-135b) = 0.017; Adj. p-value (miR-155) = 0.0022) versus never-smoking 
Down-regulated in CS-exposed mice miRBase release 21 Fold change Adjusted p-value
mmu-miR-294 mmu-miR-294-3p 3.289 0.004
mmu-miR-470x mmu-miR-470-3p 3.155 0.014
mmu-miR-188-5p mmu-miR-188-5p 2.646 0.014
mmu-miR-29bx mmu-miR-29b-1-5p 2.469 0.018
mmu-miR-376bx mmu-miR-376b-5p 2.387 0.025
mmu-miR-326 mmu-miR-326-3p 2.304 0.018
mmu-miR-805 2.079 0.014
mmu-miR-345-5p mmu-miR-345-5p 1.862 0.043
mmu-miR-375 mmu-miR-375-3p 1.812 0.002
mmu-miR-434-3p mmu-miR-434-3p 1.757 0.018
mmu-miR-678 mmu-miR-678 1.701 0.043
mmu-miR-378 mmu-miR-378-5p 1.658 0.025
mmu-miR-30a-3p mmu-miR-30a-3p 1.595 0.002
mmu-miR-30e-3p mmu-miR-30e-3p 1.565 0.043
mmu-miR-10a mmu-miR-10a-5p 1.553 0.010
mmu-miR-449 mmu-miR-449a-5p 1.506 0.034
mmu-let-7e mmu-let-7e-5p 1.499 0.007
mmu-miR-872x mmu-miR-872-3p 1.488 0.002
mmu-miR-218 mmu-miR-218-5p 1.481 0.014
mmu-miR-205 mmu-miR-205-5p 1.466 0.007
mmu-miR-193b mmu-miR-193b-3p 1.458 0.002
mmu-let-7c mmu-let-7c-5p 1.451 0.007
mmu-let-7d mmu-let-7d-5p 1.420 0.018
mmu-miR-29ax mmu-miR-29a-5p 1.408 0.043
mmu-miR-148a mmu-miR-148a-3p 1.393 0.018
mmu-miR-130a mmu-miR-130a-3p 1.377 0.004
mmu-miR-30e mmu-miR-30e-5p 1.364 0.007
mmu-miR-200a mmu-miR-200a-3p 1.353 0.002
mmu-miR-26a mmu-miR-26a-5p 1.339 0.002
mmu-miR-152 mmu-miR-152-3p 1.328 0.010
mmu-let-7g mmu-let-7g-5p 1.328 0.003
mmu-let-7b mmu-let-7b-5p 1.321 0.004
mmu-miR-34c mmu-miR-34c-5p 1.307 0.003
mmu-miR-30c mmu-miR-30c-5p 1.295 0.034
mmu-miR-30d mmu-miR-30d-5p 1.287 0.004
mmu-miR-30a-5p mmu-miR-30a-5p 1.280 0.006
mmu-miR-708 mmu-miR-708-3p 1.264 0.043
mmu-miR-34b-3p mmu-miR-34b-3p 1.264 0.025
mmu-miR-22x mmu-miR-22-5p 1.263 0.043
mmu-miR-34cx mmu-miR-34c-3p 1.253 0.034
Table 5. Down-regulated microRNAs in bronchoalveolar lavage supernatant following 24 weeks of cigarette 
smoke exposure. First column: annotation of miRNA during microRNA profiling; Second column: annotation 
of miRNA according to miRBase release 21.
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controls and in mice following chronic CS-exposure (Adj. p-value (miR-135b and miR-155) = 0.004) (Fig. 6a) 
(Table S2).
Second, by integrating data from patients participating in the GLUCOLD study where miRNA expression was 
newly profiled in bronchial biopsies between current-smoking and ex-smoking patients with moderate to severe 
COPD, we found an overlap for miR-31* with miRNA profiling in lung tissue of mice chronically exposed to CS 
compared to air-exposed mice (Fig. 6b), but also with lung tissue of current-smoking COPD patients compared 
to never-smokers (adj. p-value = 0.012 in GLUCOLD study; adj. p-value = 0.0012 in lung tissue of COPD patients 
and adj. p-value = 0.004 in mice)13 (Table S3). The clinical characteristics of the GLUCOLD study cohort can be 
found in the online Table S1.
Third, in previously published miRNA profiling data, assessed by the stem-loop RT-qPCR, in induced sputum 
supernatant of current smoking patients with COPD compared to never-smokers, 8 miRNAs were significantly 
down-regulated in COPD8. Of these 8 miRNA, 5 miRNAs overlapped with the miRNA profile obtained in BAL 
supernatant of mice chronically exposed to CS compared to air-exposed mice (Fig. 6c). Remarkably, let-7c and 
miR-218 were significantly reduced (Table S4).
Suplementary Figure S6 shows the sequence conservation between these overlapping human and murine 
miRNAs.
Figure 3. miRNAs that are differentially expressed in both lung tissue and BAL supernatant following (a) 4 
weeks of CS exposure and following (b) 24 weeks of CS exposure.
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Discussion
We have developed a murine model in which CS inhalation – the main etiologic agent in most COPD cases – ini-
tiates COPD-like manifestations, enabling us to investigate the CS-induced pathogenesis of COPD14. Using these 
mice, we observed smoke-induced inflammation in BAL and lungs which coincided with changes in miRNA 
expression in those two compartments. To our knowledge, this is the first time that both lung and BAL superna-
tant have been thoroughly investigated regarding the miRNA profile.
Figure 4. Inflammation in BAL following 4 and 24 weeks of air or CS exposure. (a) Total cell numbers in BAL, 
(b) Total macrophages in BAL, (c) Total neutrophils in BAL, (d) Total dendritic cells (DCs) in BAL, (e) Total 
CD4+ T cells in BAL, (f) Total CD8+ T cells in BAL. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 5. Spearman correlation analyses between the expression of (a) miR-135b and % dendritic cells (DCs) 
in lung following 4 weeks of air or CS exposure. Spearman correlation analysis between the expression of (b) 
miR-155 and % B cells in lung, (c) miR-21 and total macrophage numbers in BAL supernatant, (d) miR-146a 
and total neutrophil numbers in BAL supernatant and between (e) miR-218 and total neutrophils in BAL 
supernatant following 24 weeks of air or CS exposure.
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Several miRNAs were strongly affected by smoke in lung tissue and BAL supernatant. Remarkably, we did not 
observe an overall down-regulation upon CS exposure in lung as is frequently noted in other miRNA profiling 
studies7,15–17.
By focusing on the overlap between subacute and chronic CS exposure within the same compartment, or the 
overlap between miRNAs with altered expression levels in BAL and lung, we narrowed the pool of interesting 
miRNAs down to 18: let-7b, let-7c, miR-135b, miR-138, miR-146a, miR-148a, miR-152, miR-155, miR-21, miR-
26a, miR-30a-5p, miR-30c, miR-31, miR-31*, miR-322*, miR-342-3p, miR-376b* and miR-449.
We also assessed whether miRNA profiles clustered together between BAL and lung samples and whether the 
effect of smoke on the miRNA profile could be distinguished from air-exposed mice (Supplementary Figure S3). 
The clear separation in miRNA expression between BAL fluid and lung mirrors its different cellular content and 
structural organization. Moreover, lung tissue was obtained from lavaged mice, meaning that all BAL cells were 
removed. Also, smoking obviously affected miRNA profiles, both in lung as in BAL supernatant. As expected, a 
higher diversity in immune cells – often in a more activated state – and a greater amount of cells populate the 
airways and alveolar spaces following CS exposure, which could lead to a global increase in miRNA abundance 
in BAL supernatant, favoring certain immune cell-specific miRNAs. To correct for this, we normalized with the 
mean expression of all miRNAs, rendering a profile relative to this global shift.
Figure 6. Overlap in miRNA expression between mice following chronic CS exposure and patients with 
COPD. (a) Differential miRNA expression was evaluated in lung tissue of mice that were exposed to 24 weeks 
of air or CS (n = 8 per group), and in lung tissue of current smoking patients with COPD GOLD II (n = 12) 
compared to never-smokers (n = 8). (b) Differential miRNA expression was evaluated in lung tissue of mice 
that were exposed to 24 weeks of air or CS, and in bronchial biopsies of current smoking patients with COPD 
GOLD II-III (n = 42) compared to ex-smoking patients with COPD GOLD II-III (n = 21). (c) Differential 
miRNA expression was evaluated in cell-free bronchoalveolar lavage fluid of mice that were exposed to 24 weeks 
of air or CS (n = 8 per group), and in induced sputum supernatant of current smoking patients with COPD 
GOLD I-II (n = 12) compared to never-smokers (n = 10). Numbers of differentially expressed miRNAs are 
represented as well as the number of overlapping miRNAs. For the overlapping miRNAs, the direction of change 
in expression following chronic CS exposure /current smoking and having COPD is indicated with arrows. The 
level of change in miRNA expression can be found in the online supplement (Tables S2–4). COPD: chronic 
obstructive pulmonary disease, GOLD: Global Initiative for Chronic Obstructive Lung Disease.
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CS exposure altered immune cell subsets both in lung and in BAL, as well as it affected miRNA expression 
levels. We correlated miRNA expression with numbers of inflammatory cells in BAL and lung and found that 
many of our initially indicated interesting miRNAs were highly correlated. This could mean that altered miRNAs 
could be implicated in recruitment of these immune cells to the lung or airways, or that they are highly immune 
cell-specific.
Interestingly, an overlap was observed for miR-135b, miR-148a, miR-149, miR-155, miR-191, miR-31 and 
miR-31* between lungs of mice chronically exposed to CS and smoking patients with COPD compared to 
non-smoking controls, suggesting a potential role for these miRNAs in the pathogenesis of COPD7. In addition, 
there was also an overlap for miR-31* between these aforementioned two groups with patients with moderate 
to severe COPD participating in the GLUCOLD study where the differential miRNA expression was assessed 
between current- and ex-smoking patients13. By surveying the overlap between miRNA profiling data in human 
sputum supernatant of current smokers with or without airflow limitation compared to never-smokers, and our 
results in murine BAL supernatant, we found several miRNAs that were concordantly reduced including let-7c, 
miR-218, miR-26a and miR-449. Although detected in both human sputum and murine BAL supernatant, some 
miRNAs were expressed in the opposite direction such as miR-146a, miR-342-3p and miR-1508.
Regarding miRNA alterations in lung, gradual elevation of miR-155 is generally expected due to its inherent 
involvement in inflammation since miR-155 modulates both the innate and adaptive immune system18–21 and is 
induced following toll-like receptor (TLR) activation. In agreement with our data, an increase in miR-135b-5p 
expression was already demonstrated in lungs of mice that were exposed to CS for 4 days and for 18 months, 
besides the observation that miR-135b-5p is also highly inducible upon challenge of the airways with other nox-
ious particles22–24. It is also not surprising that miR-21 is up-regulated in BAL supernatant and in lung tissue. 
First, miR-21 is suggested to be concordantly expressed between tumor tissue and matched plasma or serum25,26. 
Second, miR-21 is up-regulated in activated immune cell subsets accumulating in the lung upon an inflamma-
tory stimulus, explaining its gradual increase following prolonged smoke exposure. Third, miR-21 is primarily 
expressed in cells of the macrophage lineage that are already present in the airways without prior CS trigger. 
Macrophages increase in number following CS exposure but not to the same extent as the newly arrived other 
immune cells present in BAL, explaining the only moderate increase in miR-21 expression in BAL supernatant.
As expected, miR-21 correlated with macrophage numbers in BAL. Additionally, miR-21 also correlated with 
MCP-1 protein expression in BAL. It has been shown in a mouse model of abdominal aortic aneurysm that mice 
exposed to nicotine displayed higher miR-21 levels, which was associated with a reduction in tumor suppressor 
genes, as well as with an augmentation of inflammatory genes such as IL-6 and MCP-1. Moreover, administering 
a pre-miR-21 to these mice augmented MCP-1 levels27. miR-155, although highly correlated with most immune 
cell types, showed high association (Rs > 0.750) with B cell, CD11b+DC and monocyte-derived CD11b+DC num-
bers, highlighting its intricate role in B cell and DC functionality28,29. Interestingly, reduced miR-218 expression 
was negatively correlated (Rs < −0.750) with both neutrophils, B cells, T cells and DC numbers, suggesting that a 
reduced miR-218 expression could be implicated in directional migration of these cell types towards the inflamed 
lung7. In addition, our results highlight a strong association of miR-31* with active smoking in mice and both 
cohorts of patients with COPD, as well as with DC subsets. An association of miR-31* with DC numbers is in 
agreement with a robust increase in both miR-31 transcripts in myeloid dendritic cells upon TLR stimulation in 
hypoxic conditions30.
These results put forward some interesting miRNAs considerably altered following CS exposure both in 
lung tissue and BAL supernatant of matched murine samples. Correlation of altered miRNA expression with 
the change in inflammatory profile, suggests a possible implication of these miRNAs in CS-induced inflamma-
tion. Evaluating the miRNA expression profile in two different respiratory compartments augments the relevance 
of our findings, although mechanistic data are lacking. Interestingly, we translated some of our findings to the 
human situation by discussing the overlap between our murine data and miRNA profiling data in human sputum 
and lung7,8.
In conclusion, we highlight some interesting miRNAs in the CS-induced inflammation in the lung by integrat-
ing in vivo miRNA profiling data in both BAL supernatant and lung following subacute and chronic CS exposure 
and in silico correlations with inflammatory parameters. Future research will be needed to investigate the exact 
impact of these miRNAs in the CS-induced inflammation and the pathogenesis of COPD.
Methods
Mice. Male C57BL/6 wild-type (WT) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, 
USA). All mice were kept under a 12 h light-dark cycle in autoclaved cages and bedding, with unlimited access to 
water and food. The ethics committee for animal experimentation of the faculty of Medicine and Health Sciences 
(Ghent University) approved all in vivo manipulations which were carried out in accordance with guidelines on 
animal care and welfare. In total, 32 mice were used in this study.
Smoke exposure. Mice (n = 8 per group) were exposed to air or CS, as described previously14. Briefly, mice 
were exposed whole body to the mainstream tobacco smoke of 5 simultaneously lit 3R4F reference cigarettes 
(without filter, University of Kentucky, Lexington, KY), 4 times a day with a 30 minutes smoke-free interval. 
3R4F reference cigarettes contain 9.4 mg tar, 0.73 mg nicotine, 12.0 mg CO and 11.0 mg total particulate matter, 
as provided by the supplier. The mice were placed in a plexiglass chamber of 7500 cm3, connected to a smok-
ing chamber14. Carboxyhemoglobin levels in blood were 8.35 ± 0.47% in CS-exposed mice and 0.65 ± 0.25% 
in air-exposed mice. The mice were exposed for 5 days per week, for 4 weeks (subacute exposure) or 24 weeks 
(chronic exposure). An optimal smoke-to-air ratio of 1:6 was maintained. The control groups were exposed to air.
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Bronchoalveolar lavage (BAL). Via a tracheal cannula, lungs were first lavaged using 3 times 300 µl HBSS 
(free of Ca2+ and Mg2+ and supplemented with 1% BSA). Supernatant of this fraction was used for ELISA and 
collected for miRNA profiling. Then, lungs were lavaged using 3 times 1 ml HBSS supplemented with 0.6 mM 
EDTA. The six lavage fractions were pooled, centrifuged, and the cell pellet was resuspended in 200 µl FACS 
buffer (PBS supplemented with 1% BSA, 5 mM EDTA and 0.1% sodium azide). Subsequently, total cell counts 
were obtained using a Bürker chamber and differential cell counts (on at least 400 cells) were performed on 
cytocentrifuged preparations after May-Grünwald-Giemsa staining. Furthermore, BAL cells were used for flow 
cytometric analysis.
Preparation of single cell suspension of lung tissue. Following BAL, the pulmonary and systemic cir-
culation was rinsed with saline, supplemented with 5 mM EDTA. The left lung was used for histology, as described 
previously14. The major lobe of the right lung was taken and thoroughly minced, enzymatically digested and 
subjected to red blood cell lysis. After passage through a 50 µm cell strainer, cells were counted with a Z2 particle 
counter (Beckman-Coulter, USA) and left on ice until labeling for further flow cytometric analysis. Another lobe 
of the right lung was stored for RNA extraction which was later used for miRNA profiling.
Quantification of inflammation. Flow cytometry was used to enumerate inflammatory cells in BAL 
fluid and in lung tissue. The analysis was performed on a FACS Calibur (4 weeks exposure experiment) or an 
LSR Fortessa (24 weeks exposure experiment) (BD Biosciences, San Diego, USA) and data were analyzed with 
FlowJo software (Tree Star Inc., Ashland, USA). The flow cytometry data in BAL were supplemented with cyto-
spin counts. Chemokines (MCP-1 and KC) were measured in BAL via commercially available ELISA kits (R&D 
systems).
RNA extraction. Total RNA from lung tissue and 100 µl of cell-free BAL supernatant was extracted using the 
miRNeasy mini kit (Qiagen) according to the manufacturer’s instructions. Afterwards, RNA was collected and 
measured using the Nanodrop 2000 (Thermo Fischer Scientific).
miRNA profiling on lung tissue of mice that were exposed to air or CS for 4 or 24 weeks. Total 
RNA, including the small RNA fraction, was reverse transcribed with the miRNA reverse transcription kit 
(Applied Biosystems, Life Technologies) in combination with a stem-loop Megaplex miRNA primer pool 
(Applied Biosystems, Life Technologies) consisting of primers for 523 miRNAs and 15 endogenous controls as 
described previously31. After this RT reaction the cDNA was pre-amplified using the TaqMan PreAmp Master 
Mix and Primer Mix (Applied Biosystems, Life Technologies). This pre-amplification increases the detection 
sensitivity. The pre-amplified cDNA was diluted 1,600 times. qPCR amplification of 523 mature miRNAs was 
performed using miRNA TaqMan assays (Applied Biosystems, Life Technologies). The qPCR mixture contained 
4 µL of Universal qPCR mastermix, 3 µL of a 1/15 dilution of miRNA TaqMan assay, and 1 µL of diluted pream-
plified cDNA. All reactions were run on a 7900HT qPCR cycler (Applied Biosystems, Life Technologies) under 
the following cycling conditions: 10 min at 95 °C followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C. If the 
Cq-value was below 32, the miRNAs were considered expressed. The miRNA expression data were normalized 
using the global mean32,33.
Only miRNAs that could be detected (had a Cq-value < 32) in at least 80% of the samples per group were 
included in our study, resulting in 225 miRNAs out of 523 in mouse lung.
miRNA profiling on bronchoalveolar lavage supernatant of mice that were exposed to air or 
CS for 4 or 24 weeks. The same workflow was followed for miRNA profiling on cell-free murine BAL 
supernatant.
Human study population. Overlap of murine miRNA profiling data was assessed with 3 different human 
patient cohorts. First, miRNA profiling was newly performed on bronchial biopsies from current smoking 
patients with COPD GOLD II-III (n = 42) compared to ex-smoking patients with COPD GOLD II-III (n = 21) 
participating in the GLUCOLD study34. The inclusion criteria for this study required participants without ICS 
treatment for 6 months and more than 90% of the patients were steroid naïve, i.e. had never used corticosteroids. 
The GLUCOLD study was approved by the local medical ethics committee of both the Leiden and Groningen 
University Medical Centers (LUMC and UMCG) and all patients gave their written informed consent. All meth-
ods were carried out in accordance with the research guidelines of the Groningen and Leiden Universities34. The 
clinical characteristics of the GLUCOLD study cohort can be found in Table S1.
Second, we also focused on overlapping murine miRNAs with previously published human miRNA profiling 
data. A miRNA profiling was performed on a) induced sputum supernatant and b) on lung tissue of current 
smoking patients with COPD compared to never-smokers7,8.
miRNA expression profiling on human bronchial biopsies. Endobronchial biopsies from the 
GLUCOLD study were immediately snap-frozen and stored at −80 °C. RNA was extracted using the miRNeasy 
mini kit (Qiagen) according to the manufacturer’s protocol. Purity of RNA fractions was checked on NanoDrop 
1000 UV-Vis spectrophotometer and RNA integrity was verified using RNA 6000 Pico Assay RNA chips run on 
an Agilent 2100 Bio analyzer (Agilent Technologies, Palo Alto, CA). Microarray hybridization was performed 
at the Boston University Microarray Resource Facility as described in FlashTag™ Biotin HSR Labeling Kit 
(Affymetrix, Santa Clara, CA, current version available at www.affymetrix.com).
Annotation of miRNA. Annotation of all differentially expressed miRNAs was updated using miRBase 
tracker35 in Tables 1 and 2 and Supplementary Figures 1 and 2.
www.nature.com/scientificreports/
13SCieNTiFiC RepoRts | 7: 12871  | DOI:10.1038/s41598-017-13265-8
Statistical analysis. Continuous variables were analyzed using non-parametric tests i.e. Mann-Whitney U 
test when comparing unrelated data using SPSS 24.0 software (SPSS Inc, Chicago, IL, USA). Heatmaps were gen-
erated using the heatmap.2 function from the gplots package36, where samples were clustered using manhattan 
distances and the Ward’s method (R statistical programming language, version 3.3.1)37. Spearman rank correla-
tion tests between expressed miRNAs from lung and BAL, and a) flow cytometry data in lung and BAL, respec-
tively; b) cytospin data in BAL; c) cytokine/chemokine levels in BAL, were carried out using the cor.test function 
(R software, version 3.3.1). For the correlation analysis, all miRNAs were included when expressed in at least 
half of the murine samples. Data were kept when Rs ≥ 0.5 and adjusted p-value ≤ 0.05. The Benjamini-Hochberg 
procedure was used for multiple testing correction and p-values < 0.05 were considered statistically significant.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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